ASH Takeaways

American Society of HematologyThe all-virtual 62nd ASH Annual Meeting & Exposition featured continued advancements in the treatment of hematologic malignancies. Overall themes highlight significant progress in development of immune therapies including bi-specific antibodies, CAR-T therapies, and others with novel mechanisms of action.


Below, we highlight some key studies (and their results) presented in MM, AML, CLL, and FL. 


Multiple Myeloma (MM)

  • A Phase 1 study of relapsed/refractory MM (RRMM) patients treated with Belantamab Mafodotin (anti-BCMA) in combination with Pomalidomide and Dexamethasone yielded high response rates (ORR = 86%)

  • Another Phase 1 studied a heavily pre-treated RRMM population that was treated with the FcRH5/CD3 bispecific antibody cevostamab, resulting in an ORR of 52%

  • Quadruple therapy yielded 69% CR rate, and 94% after two years of maintenance with daratumumab


Acute Myeloid Leukemia (AML)

  • A Phase 1b trial of magrolimab, an anti-CD47 monoclonal antibody, demonstrated high overall response rates within a cohort of previously untreated patients who are ineligible for intensive chemotherapy, yielding overall response rates of 63% within the overall population and 69% within TP53-mutant patients

  • Flotetuzumab, bi-specific antibody drug targeting both CD123 and CD3, demonstrated 31.8% response (CR/CRh/CRi) rate in patients with primary induction failure (PIF) and early relapsed (less than six months, or ER6) patients


Chronic Lymphocytic Leukemia (CLL)

  • The Phase 2 CAPTIVATE study randomized patients with undetectable MRD to either placebo or ibrutinib, resulting in a 95% 30-month progression-free survival (PFS) rate and indicating comparable survival rates without continued single agent ibrutinib after initial combination treatment


Follicular Lymphoma (FL)

  • Phase 2 ZUMA 5 demonstrated 76% of patients with FL/MZL treated with axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy experienced complete response